Resonic — Finite-Lived Intangible Assets, Fair Value Disclosure
Products & Services · Finite-Lived Intangible Assets, Fair Value DisclosureAnalysis
StatementSegment
CategoryCapital Allocation
SignalHigher is better
VolatilityModerate
First reportedQ3 2025
Last reportedQ3 2025
How to read this metric
An increase in fair value may indicate successful development or market validation of the underlying technology, while a decrease often signals impairment or the natural amortization of asset value over time.
Detailed definition
This metric represents the estimated fair value of finite-lived intangible assets specifically associated with the Reson...
Peer comparison
Peers in the pharmaceutical and medical device sectors report similar fair value disclosures for acquired intangible assets, often categorized by therapeutic area or specific product acquisition.
Metric ID:
abbv_segment_resonic_finite_lived_intangible_assets_fair_value_disclosureHistorical Data
1 periods
| Q3 '25 | |
|---|---|
| Value | $407.00M |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is AbbVie's resonic — finite-lived intangible assets, fair value disclosure?
- AbbVie (ABBV) reported resonic — finite-lived intangible assets, fair value disclosure of $407.00M in Q3 2025.
- What does resonic — finite-lived intangible assets, fair value disclosure mean?
- The current estimated market value of the specific intangible assets, such as patents and technology, belonging to the Resonic product line.